Gas vesicles (GVs) are a unique class of gas-filled protein nanostructures that are detectable at subnanomolar concentrations and whose physical properties allow them to serve as highly sensitive imaging agents for ultrasound and MrI. Here we provide a protocol for isolating GVs from native and heterologous host organisms, functionalizing these nanostructures with moieties for targeting and fluorescence, characterizing their biophysical properties and imaging them using ultrasound and MrI. GVs can be isolated from natural cyanobacterial and haloarchaeal host organisms or from Escherichia coli expressing a heterologous GV gene cluster and purified using buoyancy-assisted techniques. they can then be modified by replacing surface-bound proteins with engineered, heterologously expressed variants or through chemical conjugation, resulting in altered mechanical, surface and targeting properties. pressurized absorbance spectroscopy is used to characterize their mechanical properties, whereas dynamic light scattering (Dls)and transmission electron microscopy (teM) are used to determine nanoparticle size and morphology, respectively. GVs can then be imaged with ultrasound in vitro and in vivo using pulse sequences optimized for their detection versus background. they can also be imaged with hyperpolarized xenon MrI using chemical exchange saturation transfer between GV-bound and dissolved xenon-a technique currently implemented in vitro. taking 3-8 d to prepare, these genetically encodable nanostructures enable multimodal, noninvasive biological imaging with high sensitivity and potential for molecular targeting.
IntroDuctIon
The study of biological function and disease, and the development of clinical diagnostics require technologies for noninvasive imaging of cells and molecules in intact organisms. Ultrasound and MRI are two widely used noninvasive imaging modalities that provide high spatial and temporal resolution but are currently restricted in their molecular imaging capabilities because of limited repertoires of nanoscale contrast agents. For ultrasound, conventional imaging agents based on microbubbles-micron-sized particles of trapped gas stabilized by a lipid or protein shell-are limited by their size and physical instability to labeling the vasculature and endovascular targets 1, 2 . Conventional MRI contrast agents based on superparamagnetic iron oxides 3, 4 or lanthanide chelates 5 are limited by their potential toxicity and the requirement that they be present at relatively high concentrations (typically in the micromolar range) for detection by MRI.
Development of the protocol
To develop biomolecular imaging agents addressing the aforementioned limitations, we recently introduced a new class of molecular imaging agents for ultrasound and MRI based on GVs-genetically encoded gas-filled protein nanostructures from buoyant photosynthetic microorganisms 6, 7 . GVs comprise a protein shell with a hydrodynamic diameter of ~200 nm and thickness of ~2 nm enclosing a hollow gas-filled interior 6, 7 . Gas dissolved in the surrounding media partitions freely in and out of this nanoscale compartment, whereas liquid water is excluded by the shell's hydrophobic inner surface. Microbes such as the cyanobacterium Anabaena flos-aquae (Ana) and the archaeon Halobacteria salinarum (Halo) form GVs as a means to regulate cellular buoyancy for optimal access to light and nutrients. In these organisms, GVs are encoded by operons of 8-14 genes, which include the primary structural proteins GvpA and GvpC and several minor constituents and chaperones 6, 7 .
We recently discovered that GVs purified from cyanobacteria and haloarchaea scatter sound waves and thereby produce ultrasound contrast at subnanomolar concentrations 8 . Furthermore, we found that GVs' unique physical properties enable them to produce harmonic ultrasound signals useful for contrast specificity in vitro and in vivo 9, 10 . We also showed that GVs from different species can be imaged in multiplex on the basis of their differential responses to acoustic pressure, and that conditional GV clustering leads to contrast enhancement, allowing them to be used as molecular sensors 8 . In parallel, we demonstrated that GVs produce contrast in hyperpolarized xenon MRI 11 , an emerging form of imaging that takes advantage of nonequilibrium spin polarization to increase molecular sensitivity by factors of up to 10 5 . We discovered that atoms of hyperpolarized 129 Xe dissolved in aqueous media exchange in and out of the GV interior, where their distinct chemical shift enables amplified MRI contrast to be produced using chemical exchange saturation transfer (CEST) pulse sequences. Using this hyperpolarized CEST (HyperCEST) technique allows GVs to be detected at picomolar concentrations 11 . In addition, the distinct chemical shifts of GVs in different microbial species enable multiplexed imaging. HyperCEST is currently performed in vitro but is advancing toward in vivo use 12, 13 .
One particularly promising aspect of GVs is the possibility of engineering their physical and biochemical properties at the genetic level. To take advantage of this possibility, we recently developed a convenient genetic engineering platform in which a single target protein, GvpC, on the surface of GVs purified from Heterologous production of Mega GVs in E. coli is accomplished by expression from a plasmid encoding a Mega GV gene, followed by detergent-mediated lysis 11 .
The procedures leading from inoculation of GV-producing microbes to harvesting and purification are summarized in the Table 2 , along with important parameters that affect processing time, yield and quality.
Growth conditions are chosen to facilitate optimal proliferation of each host strain and GV expression. One unusual variable to keep track of is pressure, as GVs collapse irreversibly at hydrostatic pressures of 50-800 kPa, depending on species 6 . For example, the cultures should be grown under mild agitation, as excessive shaking may lead to GV collapse. During centrifugation steps, it is necessary to calculate the hydrostatic pressure generated for a particular g force on the liquid column of GVs and to ensure that it is well below the GV critical collapse pressure. Long-term storage of purified GV stocks should preferably be done in screw-top vials, as microcentrifuge tubes with snap-lock caps may cause GV collapse due to pressurization of the sample while opening or closing the tube.
Quantification and characterization of GVs. Purified GVs resuspended in the buffer of choice (e.g., PBS) can be quantified by measuring the OD at 500 nm (OD 500 ), as GVs scatter visible light (Step 2). Collapsed GVs (in the same buffer), which do not scatter light, are typically used as the blank control for measurements, yielding a pressure-sensitive OD reading (OD 500, ps ). It is important to note that clustering of GVs, whether by design or due to functionalization with aggregation-prone moieties, can confound OD 500 measurements and contribute to errors in calculating concentration from OD 500 . Pressurized absorbance spectroscopy assays GV mechanical strength by measuring OD 500 under increasing hydrostatic pressure using the device described in the Equipment Setup section (Fig. 3) and the protocol described in Step 46A(i-ix).
DLS is used to estimate the hydrodynamic size of GVs for routine nondestructive characterization and quality control ( Step 46B(i-ii)). DLS can be used to assess GV clustering. Care should be taken in the interpretation of DLS readings of GVs because of the spherical assumption of the Einstein-Smoluchowski relation and the nonspherical shape of GVs. Negative-contrast TEM is used for imaging GV size, shape, texture and integrity following production and physical or biochemical treatments ( Step 46C(i-viii)). Negative staining with uranyl acetate is used to produce contrast, and use of a buffer such as HEPES is preferred over use of phosphate buffers that may precipitate with the uranyl acetate. The concentration of the GV solution spotted on the grid directly correlates with the density of GV particles on the grid. Modification and functionalization of GVs. GVs can be modified and functionalized through genetic and chemical methods.
Genetic engineering of GV mechanical and surface properties is conveniently performed via exchange of the native outer scaffolding protein GvpC (gas vesicle protein C) with recombinant GvpC variants (Steps 11-41). For example, fusing short peptides to the termini of GvpC allows for cell-specific targeting, and truncated GvpC variants enable acoustic multiplexing 14 . GvpC tolerates terminal fusions of peptides of up to 100 residues. To covalently attach larger proteins, one can use the modular SpyTagSpyCatcher protein assembly system 17 . GVs reconstituted with SpyTag-GvpC can be reacted with proteins of interest fused to SpyCatcher, forming a covalent bond (Steps 42-45).
Chemical conjugation to GVs makes use of lysine residues on their protein shells and amine-reactive cross-linkers such as sulfo-N-hydroxysuccinimide esters (Sulfo-NHS). Chemical moieties, including polymers (e.g., PEG), fluorophores and small molecules (e.g., biotin), can be conjugated using this method (Steps 4-10). Biotinylated GVs can subsequently react with streptavidin or avidinated antibodies 8 . The Sulfo-NHS coupling reaction can be conducted in PBS (pH 7.4) as a one-pot reaction. Depending on the application, the desired extent of labeling can be tuned by varying the molar ratio of Sulfo-NHS to GVs and by changing the incubation time. Either dialysis or buoyancy purification can be used to separate the labeled GVs from excess reactants.
Ultrasound imaging of GVs. For in vitro imaging, GVs can be embedded and imaged in multiwell agarose phantoms (Fig. 4a , Steps 47-62). A typical experimental setup for in vitro and in vivo ultrasound imaging is shown in Figure 4 . Experimental design parameters include phantom composition (i.e., percentage of agarose, buffer, background scattering particles), concentration and amount of GV sample loaded. Phantom molds can be made using 3D printing to obtain a defined well size, shape and spacing. Imaging parameters include plane of imaging (longitudinal versus transverse cross-section of the phantom wells), mode of In vivo imaging setup with the Verasonics L22-14v transducer, mounted on a 3D positioning system (manual), an animal-mounting platform with a heating pad and a syringe pump for controlled sample injections. (c) Setup of the Vevo imaging station includes the ultrasound probe clamp attached to the 3D stepper, the mouse handling table and the physiological monitoring unit. All components except the physiological monitoring unit are attached to the benchtop rail system. (d) Animal positioning, with the mouse being laid down in a supine position with the nose and mouth in the nose cone and each paw extending outward onto the electrodes and secured with surgical tape. A rectal probe is used to monitor the core temperature of the animal. All procedures involving animal use must be performed in accordance with institutional guidelines and regulations and approved by relevant animal care and use committees. All animal experiments reported in this article received approval from the institutional animal care and use committees of the California Institute of Technology or the Sunnybrook Research Institute. ultrasound imaging (conventional or nonlinear imaging), transducer frequency range, transmit waveform characteristics such as pulse envelope shape, number of cycles, amplitude and frequency. Importantly, the amplitude used for imaging must be below the GVs' acoustic critical collapse pressure. PBS is typically used as a negative control for ultrasound contrast and 5-µm polystyrene beads that scatter linearly at medical ultrasound frequencies are used as a reference sample. All GV samples and controls are mixed with melted agarose solution before loading. Solidification of the agarose after loading into the phantom wells ensures that samples are uniformly distributed throughout the well and that GVs remain suspended in the agarose matrix without floating during imaging. Typically, a final OD 500 value of 2.25 for Ana GVs and 0.4% (wt/vol) for polystyrene beads is used to match echogenicity. For Halo GVs, a final OD value of 0.5 gives good signal without attenuation, with 0.83% (wt/vol) polystyrene beads to match echogenicity. In situ collapse of GVs using pulses with amplitudes above the GVs' acoustic critical collapse pressures cause GV ultrasound signals to disappear, allowing confirmation of GV-based signals and background subtraction. In addition, differential collapse at multiple pressures and spectral unmixing allow multiplexed imaging of mechanically distinct GV classes 14 . Quantification of signals in ultrasound images is typically performed using MATLAB or ImageJ software.
The in vivo ultrasound imaging protocol has been used to look at GV passage through the inferior vena cava (IVC) and subsequent induced contrast enhancement in the liver after i.v. injection 8, 14 ( Step 63A-B), but it can be adapted for other organs or tissues. Depending on the tissue region of interest, some ultrasound imaging parameters, such as image gain and field of view, may need to be adjusted accordingly. As in in vitro imaging, it is critical that the transmit power be kept at a value that provides sufficient signal without collapsing the GVs. Further adjustments can be made to GV solution concentration and volume, according to experimental needs. Functionalized GVs can also be imaged using this protocol, as long as appropriate controls are used. When planning an imaging experiment using functionalized GVs, we suggest using native GVs from the same batch as a control. It is possible to administer multiple injections of GVs in the same mouse, as long as the total injection volume does not exceed the limit stated in institutional guidelines. If required, GV solutions can be tested for bacterial endotoxins using quantitative, chromogenic endpoint LAL assays, such as the QCL-1000 Assay (Lonza). Endotoxins can potentially be removed using commercially available affinity resins such as the ToxinEraser Endotoxin Removal Resin (GenScript). Once injected, ensure that GVs have cleared completely and the tissue contrast signal is back to baseline before a second bolus injection.
129 Xe MRI imaging of GVs. Hyperpolarized 129 Xe-MRI, an active area of molecular imaging research, is currently mainly performed in vitro with pure contrast agents or labeled cells 18, 19 while in vivo techniques are being developed 12, 13 . This protocol describes the imaging of GVs using hyperpolarized 129 (e) Schematics of the communication between the NMR pulse sequence and the gas-delivery manifold, with corresponding tube and electrical connections. DAQ, data acquisition. 129 Xe is sufficient), 10% (vol/vol) N 2 , He balance, grade 5.0 (Praxair))  crItIcal The gas tank should have a pressure regulator for adjustments ~2 bar absolute pressure. The gas amount to be used Nonselective NMR pulse sequence for acquiring a direct Xe NMR spectrum after fresh Xe delivery. This is implemented by using a simple (pulse-acquire) sequence; the sequence starts with two trigger signals to communicate with the gas-delivery manifold and then a block excitation pulse of adjustable amplitude, followed by a free induction decay (FID) acquisition Multi-echo acquisition MRI pulse sequence (echo planar imaging (EPI) or rapid acquisition with relaxation enhancement (RARE), Bruker) with activatable magnetization transfer module (alternative: fat suppression or saturation transfer module) and two triggers Hyperpolarization system for producing spin-hyperpolarized 129 Xe (commercial systems are available through http://xemed.com and http://www.polarean.com or as an open-source design) ! cautIon The hyperpolarization system contains ~1 g of a highly reactive alkali metal such as Rb. Make sure to become familiar with the procedures for handling the system as provided by the manufacturer  crItIcal The system must be capable of producing hyperpolarized Xe in continuous flow mode for repeated re-delivery into the sample solution.
Gas flow controller with a maximum flow rate of 100 standard ml/min (SMLM; Omega Engineering, model no. FMA 5408) and second one of 500 SMLM flow (Omega Engineering, model FMA5412)  crItIcal Such gas-flow controllers are typically calibrated for N 2 gas; the correction factors for systems based on heat flux measurements applied to the Xe gas mix are as follows: The solution is at 1,000× concentration and should be filter-sterilized after preparation; it can be stored for up to 6 months at −20 °C. Ampicillin stock solution Ampicillin stock solution is 100 mg/ml ampicillin in dH 2 O. The solution is at 1,000× concentration and should be filter-sterilized after preparation; it can be stored for up to 3 months at −20 °C. Chloramphenicol stock solution Chloramphenicol stock solution is 25 mg/ml chloramphenicol in ethanol. The solution is at 1,000× concentration and should be filter-sterilized after preparation; it can be stored for up to 6 months at −20 °C. IPTG inducer stock solution IPTG inducer stock solution is 1 M IPTG in dH 2 O. The solution is at 1,000× concentration and should be filter-sterilized after preparation and can be stored at −20 °C in the dark for up to 1 year because it is light-sensitive.
•
GV stripping buffer (Round 1) GV stripping buffer is 10 M urea and 100 mM Tris-HCl, pH 8. Ultrasound gel preparation for imaging experiments Take a 30-ml Luer-Lok syringe, remove the piston and place the syringe with the tip facing down in a 50-ml Falcon tube. Fill the syringe with ultrasound gel before loading the Falcon tube into a table-top centrifuge. Spin at 2,500g for 30 min to ensure that there are no air bubbles in the gel, and keep it at room temperature. It is advisable to prepare the gel on the same day of the experiment, as longer storage may lead to drying if the syringe is not sealed tightly.
EQUIPMENT SETUP Cleaning and sterilization of glassware Clean and sterilize all glassware by autoclaving, and fully dry all glassware before use. Setup of the apparatus for pressurized absorbance spectroscopy The setup used to conduct pressurized absorbance spectroscopy is illustrated in Figure 3 and includes the following components: (i) computer equipped with MATLAB to run the collapse pressure scripts, (ii) compressed N 2 tank with control valves and a regulator, (iii) pressure controller, (iv) flow-through quartz cuvette and (v) UV-Vis spectrometer equipped with a light source and a cuvette holder. Couple the pressure controller to the gas tank via a stainless-steel gas connector, to the computer via a USB port and to the flow-through cuvette via plastic cannulae. Connect the ecoVis Krypton light source of the UV-visible spectrometer to a power supply, allowing light to pass through the sample in the quartz cuvette. The transmitted light then passes through an optical fiber connector into the OceanOptics STS microspectrometer. The spectrometer is connected to the computer and controlled by a MATLAB script, which also interfaces with the pressure controller (MATLAB scripts can be found in the Supplementary Data). An equilibration time of 7 s at each pressure step and a final collapse pressure of 1,400 kPa (for blanking) is hard-coded into the script and kept constant for all measurements. Before acquiring sample measurements, the system is calibrated by recording the spectra for full transmission (using the cuvette loaded with PBS or a buffer of choice) and zero transmission (by turning the cuvette 90° so that no light passes through). ! cautIon Ensure that the compressed nitrogen tank is transported and stored safely. Cylinders should be secured and stored upright in a cool, dry area protected from combustible materials. The gas valve seal must always be in place. When not in use, keep all the cylinder and regulator valves shut and the pressure controller and spectrometer powered off. replacing the phantom holder with a mouse-mounting platform equipped with a heating pad, anesthesia equipment and nose cone for the animal and a manually translatable probe clamp.  crItIcal Make sure that the probe is well coupled to the sample and that the transducer array of the probe is immersed in liquid or covered with ultrasound gel before transmitting ultrasound.
Setting up the Verasonics imaging station and imaging parameters
GVs can be imaged using the Ray-lines Verasonics example script. Imaging is typically performed at ~18 MHz using the L22-14v transducer with an F number of 2 or 3, focal depth of 8 mm (matching the natural focus of the transducer) and 6 cycle pulses. For these parameters, nondestructive imaging of GVs can be performed at voltages 3 V. The onset of GV collapse usually takes place at ~5 V. For efficient GV destruction, a 25 V pulse is applied for a few seconds.
GVs are imaged at lower frequencies (~6.25 MHz) using the L11-4v transducer and the corresponding Ray-lines script. The F number is set to 2, transmit focus to 20 mm and transmit voltage to 1.6 V. Images are saved from the Verasonics graphical user interface.
Setup of the Vevo imaging station and imaging parameters
The imaging station setup is depicted in Figure 4c ,d, and encompasses the following components: (i) benchtop rail system; (ii) 3D stepper motor; (iii) ultrasound probe clamp; (iv) mouse-handling table; and (v) physiological monitoring unit. Make sure that the 3D motor is connected to the Vevo2100 ultrasound system to allow for 3D image acquisition. Also connect the physiological monitoring unit to the Vevo2100 system to allow on-screen tracking of physiological parameters such as heart rate, respiratory rate and body temperature.
Halo GVs are imaged under the following imaging settings using the Vevo2100 system: (i) frequency-21 MHz and 18 MHz for B-mode and contrast mode, respectively; (ii) transmit power-2%; and (iii) gain-16dB and 32dB for B-mode and contrast mode, respectively. The imaging field of view can be adjusted accordingly to fit the tissue region of interest, by increasing or decreasing the image width and depth.  crItIcal It is critical to keep the transmit power on the Vevo2100 system to 2%, to allow for stable imaging of Halo gas vesicles. Higher transmit power will collapse exposed GVs. Setting up the syringe pump GV injections are administered as a bolus using a syringe pump (shown in Fig. 4b ). The following settings are used for each injection: (i) syringe diameter-3.55 mm (inner diameter of a BD 12-cc tuberculin syringe); (ii) injection rate-300 µl/min to 500 µl/min; and (iii) injection volume-50 µl. Installing the control electronics for the 129 Xe MRI Set up the TTL output of the spectrometer with the photoMOS relay such that the latter controls the status of the shortcut valve (see Fig. 5d for the circuit). This is used to alternatingly force gas flow through the sample or to bypass the sample. From the Daq/board, use one analog output to control the set points for the flow and pressure controllers. Connect one analog input each to read the process values of the controllers. Display the corresponding parameters through appropriate elements in the DASYLab/LabView software. Preparation of the Xe gas-delivery manifold The timing of Xe bubbling is controlled by the pulse sequence and achieved through a proper gas-delivery system by connecting the PFA tubing and controllers according to Figure 5e . Before each experiment, insert the (five) capillaries into the capillary holder. The end tips should reach close to the bottom of the glass phantom.  crItIcal This design of the flow and pressure controllers prevents Xe gas from passing through any needle valves or (electro)magnetic units during its transfer from the hyperpolarizer to the sample, thus minimizing the depolarization of Xe.  crItIcal Gas bubbles can cause serious image artifacts if persistent during image acquisition. Therefore, the bubbling must be stopped and the sample must settle down before acquisition. Fresh hyperpolarized xenon must be re-delivered for each subsequent acquisition. MRI pulse sequence setup The nonselective NMR sequence for acquiring direct Xe NMR spectra is adapted from an existing simple FID sequence by implementing the TTL trigger pulses and bubble/wait delays before the 90° block pulse (Fig. 5e) . The FID sampling window is typically 1,000 ms and the spectral width to cover is ~350 p.p.m. For Xe MRI imaging sequence, single-shot pulse sequences should be used to make the most efficient use of the nonrenewable Xe polarization. A single-shot EPI pulse sequence can be used when long effective transverse relaxation time (T 2 *) values are expected. Alternatively, a single-shot RARE pulse sequence can be used and is limited by T 2 . To set up the imaging sequence, take a standard sequence with image encoding of your choice (EPI or RARE) and implement a magnetization transfer or saturation module (Bruker ParaVision terminology) after the TTL trigger pulse for xenon delivery and before the k-space encoding. The saturation offsets are defined through a saturation frequency list. This list can be accessed by providing in the ParaVision graphical user interface a menu to enter a fixed number of saturation pulse frequency offsets. Point these entries to the saturation frequency list. Finally, loop the entire xenon delivery, wait time, saturation pulse and imaging sequence multiple times to walk through the entire saturation frequency list. Some general parameters when implementing the sequence are as follows: a field of view: 20 × 20 mm 2 ; matrix size: 32 × 32 (in-plane spatial resolution: 625 µm 2 ); slice thickness: 20 mm; repetition time, including saturation time and xenon delivery: ~18 s.
Detailed parameters for RARE sequence: 90° Hermite excitation pulse (length = 3.375 ms, bandwidth = 1,600 Hz); 180° Mao refocusing pulse (length = 3.105 ms, bandwidth = 2,000 Hz); short echo time (~10 ms (this is also the effective echo time, as centric encoding is used here), echo readout time of 2.66 ms).; Ensure that the RARE factor is set to give a singleshot acquisition, i.e., a RARE factor of 32 is used when the image matrix size is 32 2 .
Detailed parameters for EPI sequence: 90° Gaussian-shaped excitation pulse: length = 1.0 ms, bandwidth = 2,740 Hz; encoding: partial Fourier-acceleration factor = 1.68 (i.e., 19 out of 32 k-space lines) and double sampling; short echo time of ~ 6 ms; echo train readout time of 6.01 ms for 19 k-space lines. proceDure production and purification of GVs 1| GVs can be produced natively in cyanobacterial (Ana GVs) or haloarchaeal (Halo GVs) hosts. In addition, they can be heterologously expressed in E. coli (Mega GVs). To produce and purify Ana, Halo or Mega GVs, follow the steps in option A, B or C, respectively. (iv) Transfer the starter culture to the shaker incubator (shown in Fig. 2b ) and allow it to grow at 25 °C, 100 r.p.m. and 1% CO 2 with cycles of 14 h of light illumination and 10 h in the dark until the cells form a dense, floating green layer that is clearly visible at the top of the liquid phase. This growth typically takes ~1-2 weeks. Note that the doubling time of Ana during exponential phase is ~ 56.5 h (ref. 25) , so, depending on the number of viable cells in the starter culture, it will take 1-2 weeks to produce enough floating green cells that have the ability to produce GVs. Viable cells typically form the dense layer at the top and dead cells sink to the bottom of the tube. ? troublesHootInG (v) Subculture of Ana for GV production ( Step 1A(v and vi): timing = 2 weeks). Prepare aliquots of 200-250 ml of G625 medium in an autoclaved 1-liter Erlenmeyer flask (use a Bunsen burner flame or a laminar flow hood to provide a sterile environment to avoid contamination). Add a 1× final concentration of BG-11 freshwater solution (4-5 ml of the 50× stock) just before inoculation with Ana starter culture. Swirl to mix the components. (vi) Inoculate 2 ml of the green, floating layer of the starter culture per flask and grow cells in the incubator at 25 °C, 100 r.p.m., 1% CO 2 , 14-h light and 10-h dark cycle until they become confluent (as shown in Fig. 2b,c) . This should take ~2 weeks, with the exact time depending on the number of viable cells inoculated.
? troublesHootInG (vii) Harvesting of Ana GVs ( Step 1A(vii-xi): timing = 1 d). Pour the confluent culture from the flask into a separatory funnel (presterilized, with stopcock in place), allowing it to stand undisturbed on a metal ring stand for 12-16 h until the GV-producing Ana cells separate from the spent medium to form a compact green layer at the top (Fig. 2e) . (viii) Carefully remove most of the spent medium by opening the stopcock at the bottom of the funnel and retaining only the green fraction at the top, along with ~30 ml of medium. (ix) Using a 25-ml serological pipette, gently resuspend the cells and transfer to a 50-ml tube. (x) Use 10 ml of fresh G625 growth medium to collect the cells sticking to the walls of the funnel. Each flask should be reconstituted to ~50 ml of concentrated cell suspension.
? troublesHootInG (xi) Split the suspension into two Falcon tubes and add an equal volume of 1 M sorbitol (final concentration is 500 mM) and 10% (vol/vol) Solulyse (i.e., 5.5 ml in 55 ml) to achieve hypertonic lysis. Place the tubes in a rotatory shaker at 4 °C for 6-8 h. Green lysates will have a milky tinge post lysis due to the presence of GVs.  crItIcal step We have observed that GVs become structurally compromised by certain detergents and surfactants used routinely for cell lysis such as BugBuster (EMD Millipore), Triton-X and SDS. It is therefore advisable to thoroughly characterize the effect of any new detergent on GV structure and integrity using techniques such as TEM and pressure absorbance spectroscopy before using them for ultrasound and MRI.
? troublesHootInG (xii) Isolation and purification of Ana GVs from lysate ( Step 1A(xii-xvii): timing = 2-3 d). Transfer 35 ml of cell lysate to a 50-ml tube and centrifuge at 350g at 4-8 °C for ~24 h in a table-top centrifuge, preferably equipped with a swinging-bucket rotor.
? troublesHootInG (xiii) Slowly remove as much as possible of the green subnatant liquid and cell pellet using a 25-ml serological pipette, without disturbing the white GV layer on top. (xiv) For the second and third rounds of centrifugation (350g, 4-8 °C), resuspend the white supernatant layer containing GVs in 25 ml of sterile 1× PBS. During each resuspension step, gently wash the inner walls of the Falcon tube with fresh PBS to recover GVs sticking to the sides. The green subnatant should progressively become clearer with each spin. The second and third rounds of centrifugation are shorter than the first, with the endpoint being when all the GVs rise to the top of the tube. (xv) For the final spin, resuspend the GVs in 10-12 ml of PBS (total volume can vary, depending on GV yield) and prepare aliquots in 2-ml tubes. Spin in a microcentrifuge at 350g for 4 h at 4-8 °C.  crItIcal step Do not fill the tube to the brim, as GVs will become stuck to the lid of the tube when they float to the top during centrifugation ? troublesHootInG (xvi) Using a 21.5-gauge flat needle attached to a 3-ml syringe, maintain the angle of the microcentrifuge tube and slowly insert the needle through the GV film to the bottom. Collect most of the subnatant and slowly take out the needle. Some GV loss will occur at this step. This is OK as long as most of the GVs are not sucked into the syringe. (xvii) Resuspend the purified GVs in ~6-8 ml of PBS (exact volume of added PBS can vary and is determined by how concentrated the GV solution must be for the end application) and prepare aliquots of the milky white GV solution (Fig. 2j) in screw-top vials or microcentrifuge tubes.  crItIcal step Avoid freezing or subjecting the tube to shocks, such as dropping it to the ground or snapping the cap, as these may collapse the GVs.  pause poInt The aliquots of Ana GVs can be stored for up to a year at 4 °C. Gently pour the culture from the flask into a separatory funnel (presterilized, with stopcock in place). Allow the culture to remain undisturbed until a visible ring is formed at the top (Fig. 2f) . This typically takes 4-6 d.
? troublesHootInG (v) Remove as much of the spent medium as possible by opening the stopcock, retaining only the buoyant layer of milky pink cells for lysis. The retained volume is ~10-20 ml, and many cells stick to the sides of the funnel. (vi) Using an equal volume (10-20 ml) of TMC lysis buffer (pH 7.5), gently wash the cells stuck to the sides of the funnel and retrieve as many cells as possible. The volume of TMC buffer used may be varied according to the cell density, in order to achieve efficient hypo-osmotic lysis. However, note that if too much buffer is used in this step, the number of 2-ml aliquots will proportionately increase for the next step, thus increasing sample processing time.
? troublesHootInG (vii) Isolation and purification of Halo GVs from lysate (Step 1B(vii-xi): timing = 2 d)
. Prepare ~1.6-ml aliquots of cells in 2-ml tubes and spin in a microcentrifuge at 300g for 4 h at 4-8 °C.  crItIcal step Close the tubes gently; the pressure wave caused by snapping the lid will collapse a large number of the Halo GVs. Transform 50 µl of chemically competent Rosetta 2(DE3) pLysS cells using >1 ng of pST39 plasmid containing the pNL29 Mega GV gene cluster 15 by mixing the two components in a 1.5-ml tube and incubating on ice for 30 min. Heat-shock the tube in a 42 °C water bath for 45 s, and put the tube back on ice for 1 min. Add 500 µl of SOC outgrowth medium and incubate in a shaker at 37 °C and 250 r.p.m. for 1 h. (ii) Prepare 3 ml of LB medium containing 1× ampicillin (100 µg/ml), 1× chloramphenicol (25 µg/ml) and 1% (wt/vol) glucose in a glass culture tube. Resuspend 300 µl of the transformed E. coli in the broth. Grow the culture in a shaker incubator at 37 °C and 250 r.p.m. until the OD 600 value reaches 0.4-0.6. Make 100-µl aliquots of the culture in sterile tubes, and mix with 100 µl of 50% sterile glycerol. Freeze the tubes at −80 °C as E. coli glycerol stocks.  pause poInt The glycerol stocks can be stored at −80 °C and used for up to 3 months. Note that although using glycerol stocks is convenient, the GV yield is reduced when using frozen stocks, so we recommend fresh overnight transformations for best results. Figure 2i ,j.  crItIcal step Avoid freezing and subjecting the tube to mechanical shocks, such as dropping it to the ground or snapping the cap, as these may collapse the GVs.  pause poInt Mega GVs can be stored for up to one year at 4 °C.
Quantification of GVs by measurement of pressure-sensitive oD • tIMInG 15 min 2| Determine the concentration of a solution of GVs by measuring its pressure-sensitive OD at 500 nm (OD 500,ps ) using a NanoDrop 2000 spectrophotometer. Load 2 µl of sample onto the pedestal for each measurement. Collapsed GVs in the same buffer are used as a blank for measurements. Prepare collapsed GVs by sonication in a water bath until the solution turns completely clear or by manual collapse in a capped syringe. For manual collapse, remove the plunger from a 12-ml Luer-Lock syringe closed with a tip cap and place 5-10 µl of GV solution at the bottom of the syringe. Making sure that the tip cap is screwed on tight, replace the plunger and push down until there is substantial resistance. The increase in pressure will collapse the gas vesicles, turning the milky white solution clear. A shortcut for quick measurements of GV concentration is to use the GV resuspension buffer as a blank. For most samples, this will yield an OD reading that is very close to that measured when using collapsed GVs as a blank. However, for some samples containing GVs that are fluorescent, it is necessary to use the collapsed GVs as the blank. ! cautIon Before performing manual collapse, ensure that the tip cap on the syringe is facing away from you and is securely fastened, as pressurization of the syringe may cause ejection of the cap, resulting in potential injury to the user. Wear protective eyewear and clothing.  crItIcal step It is important to ensure that the GVs are homogeneously resuspended in solution just before measurements. For each sample, take the average OD 500,ps value after multiple measurements (n > = 3) to ensure precision and accuracy.
Quantification of GV protein concentration • tIMInG 15 min 3| Measure the protein concentrations using the Pierce 660-nm protein assay to obtain relationships between OD and protein content for the GV solutions. We have established the protein concentration to OD relationships for our three types of GVs, and the results are as shown in table 3 below (N = 4, 5 and 3 for Mega, Ana and Halo GVs, respectively, and the errors are SEMs). The molecular weight is derived from the TEM data summarized in table 4, assuming a spindle shape for Halo GVs, a cylindrical shape for Mega and Ana GVs, a wall thickness of 18 Å and a protein density of 1.4 g/ml.
chemical functionalization of GVs • tIMInG 2 d  crItIcal Purified Ana, Halo and Mega GVs contain lysine residues on the surface that can be used to chemically conjugate a variety of moieties, such as PEG, fluorophores and biotin, using an amine-reactive coupling group such as N-hydroxysuccinimide ester. 4| Measure the concentration of purified GVs using the OD relationships in table 3.
5|
Prepare aliquots of the NHS moiety in anhydrous DMSO at 100× the required molar concentration for the amine-NHS reaction. For Alexa-488-NHS conjugation to Ana GVs, add 5 µl of the 10 mM stock solution of the dye predissolved in anhydrous DMSO.  crItIcal step Ensure that the NHS moiety solution does not contain detergents or surfactants that might affect the integrity and properties of the GVs.
6|
Adjust the concentration and volume of GVs to the desired amount and ensure that the buffer is free of amines (avoid Tris buffer). For Alexa-488-NHS conjugation to Ana GVs, bring Ana GVs to an OD value of 1 in 1 ml of PBS at pH 7.4.  crItIcal step If GVs were previously in a buffer containing free amines or PBS with a pH <7, ensure complete buffer exchange with PBS at a pH of 7-9 before proceeding with the amine-NHS reaction.
7| Add a 10 5 molar excess of the NHS moiety to the GVs, keeping the DMSO concentration 0.5% of the total reaction volume. For Alexa-488-NHS conjugation to Ana GVs, add 5 µl of the 10 mM Alexa-488-NHS in DMSO to 1 ml of Ana GV solution. On the basis of the average number of GvpA and GvpC protein monomers that make up Ana GVs, ~50,000 lysine residues are present for each Ana GV. One can tune the molar ratio of the two reactants (NHS moiety/GV) to achieve the desired reaction efficiency.
8|
Allow the reaction to proceed for 4 h at room temperature under gentle rotation. ? troublesHootInG 9| Quench the unreacted NHS moieties using Tris-HCl buffer at pH 8 to a final concentration of 10 mM for 20 min at room temperature under gentle rotation 10| Add the whole reaction mixture to dialysis tubes (6-8 kDa cutoff) and dialyze against a 4,000× volume excess of PBS at 4 °C for 8 h. Replace the buffer and allow dialysis to continue for an additional 8 h.  crItIcal step If the NHS moiety is not amenable to dialysis, the use of repeated rounds of centrifugally assisted purification is an alternative method to remove excess reactants and/or for buffer exchange.
? troublesHootInG  pause poInt Chemically functionalized GVs can be stored in PBS buffer for up to 1 year at 4 °C.
(optional) Genetic modification and functionalization of ana GVs • tIMInG 3 d  crItIcal The outer scaffold protein of Ana GVs, GvpC, can be removed and replaced with genetically modified recombinant versions as a molecular handle for GV mechanical modification and functionalization. This procedure comprises stripping native GvpC from Ana GVs (Steps 11-19), preparation of recombinant GvpC (Steps 20-38) and re-adding this GvpC onto ∆GvpC Ana GVs via dialysis (Steps 39-41). In addition, GVs functionalized with GvpC fused to the SpyTag peptide enable convenient downstream covalent functionalization with proteins fused to the SpyCatcher moiety (Steps 42-45).
11| Preparation of ∆GvpC GVs (Steps 11-19: timing = 12 h).
Dilute purified Ana GVs in PBS such that the OD 500,ps value <10.
12| Prepare a 3:2 (vol/vol) mix of GV stripping buffer (Round 1; i.e., 10 M urea in 100 mM Tris buffer) and GV solution in PBS. Pipette 1.7 ml into 2-ml microcentrifuge tubes. 
15|
Remove the comb and bottom tape from the precast polyacrylamide gel. Assemble the electrophoresis cell according to the manufacturer's instructions. Fill the inner chamber completely with 200 ml of 1× TGS buffer. Ensure that the inner chamber is not leaking fluid. Fill the outer chamber up to the mark indicated on the buffer tank with 600 ml of 1× TGS buffer.
16|
Load the protein ladder and samples into the gel using gel-loading tips. GVs should be at OD 500 > 3 before the 1:1 dilution. If purified proteins are being run on the same gel for comparison, load >100 ng.  crItIcal step To prevent contamination between wells, do not exceed the maximum recommended volume per well.
17|
Connect the electrophoresis cell to the power supply and run the gel for 55 min at 120 V.
18|
Recover the gel by disassembling the electrophoresis cell and the gel cassette. Incubate the gel in a holder with ddH 2 O for 10 min, and then stain for 1 h with 10 ml of SimplyBlue SafeStain. Destain the gel for at least 1 h with 10 ml of ddH 2 O.
19|
Image the gel using a Coomassie imaging protocol, using the gel imaging system to visualize protein bands. The GvpC band at ~25 kDa should be missing.
? troublesHootInG  pause poInt Store the ∆GvpC GVs in urea buffer at 4 °C for no more than 1 week. When preparing ∆GvpC GVs for long-term storage without any further genetic functionalization or recombinant GvpC addition (Steps 39-45), we recommend dialyzing the GV solution against PBS in order to completely remove the urea.
20| Preparation of recombinant GvpC (Steps 20-38: timing = 1 d).
Transform >1 ng pure plasmid encoding recombinant GvpC with a C-terminal hexahistidine tag into BL21 (DE3) competent cells and grow the culture in terrific broth with 50 µg/ml kanamycin overnight.
21| Dilute 500 µl of the starter culture 1:1 with 50% glycerol in water and store it at −80 °C for up to one year for the best results. Future starter cultures can be grown from aliquots of this glycerol stock instead of fresh transformations.
22| Dilute the starter culture 1:250 in terrific broth with 50 µg/ml kanamycin and grow it with shaking (250 r.p.m.) at 37 °C until the OD 600 value is ~0.4-0.7. Induce at a final concentration of 1 mM IPTG. Grow the culture for 6-12 h at 30 °C with shaking at 250 r.p.m.  crItIcal step Frozen IPTG stocks should be thawed fully and vortexed to mix contents before use.
23|
Pellet the cells in ultracentrifuge tubes at 5,500g for 15 min at 4 °C and discard the supernatant.  pause poInt Cell pellets can be stored at −20 °C for up to one year. Protein extraction is typically more effective with frozen cells.
24|
Resuspend the pellets (typically from 150 ml of liquid culture) in 10 ml of Solulyse with 10 µg/ml DNase. Rotate at room temperature for 10 min.
25| Centrifuge at 20,000g for 15 min at 4 °C to clear the lysate and discard the supernatant.
26|
Resuspend the pellet in 10 ml of Solulyse and lysozyme (0.25 mg/ml). Rotate at room temperature for 10 min.
27| Add 5 ml of Solulyse and vortex. Centrifuge at 20,000g for 20 min at 4 °C and discard the supernatant. 28| Thoroughly resuspend the pellet in 10 ml of inclusion body solubilization buffer. The exact volume of solubilization buffer can be adjusted according to the amount of expression culture and the level of protein expression (i.e., based on the size of the white inclusion body pellet) in order to achieve effective resuspension. Typically,10 ml of buffer is used for a pellet from 150 ml of expression culture.
29|
Centrifuge at 30,000g for 20 min at 4 °C. 30| Add 1.5 ml of Ni-NTA slurry to the supernatant, and incubate at 4 °C with shaking (60 r.p.m.) for 2 h or more.
31|
Pour into a Poly-Prep column and collect all the flow-through, wash and elutions in the next steps. Collecting all fractions is good practice for troubleshooting and analyzing purification steps using SDS-PAGE.
32|
Wash with 10 column volumes of inclusion body wash buffer.
33|
Elute with 2 column volumes of inclusion body elution buffer to collect Elution 1. Repeat once to collect Elution 2.
34|
To quantify the eluted protein using the Bradford assay, prepare a standard curve of BSA at final concentrations of 100, 250, 500, 750, 1,000 and 1,500 µg/ml in 60 µl of 3× diluted inclusion body elution buffer in PBS. Prepare dilutions of eluted protein 1:2 in PBS with a final volume of 60 µl. Prepare a negative control of 3× diluted inclusion body elution buffer in PBS.
35|
To 25 µl of the sample and BSA standards, add 1 ml of Bradford reagent, vortex and incubate at room temperature for 5-10 min. Prepare all samples in duplicate.
36|
Blank the spectrophotometer with a negative control sample and measure the OD 595 value.
37|
Measure the OD 595 value of the standard curve samples. Plot the OD 595 value versus the concentration, and compute linear regression fit.
38|
Measure the OD 595 value of the eluted protein samples. Use the linear fit from Step 37 to compute the unknown concentrations, and multiply by 3 (dilution factor) to obtain the concentration of the stock elution solution.
? troublesHootInG  pause poInt Store Elutions 1 and 2 separately at 4 °C for up to 3 months. Elution 1 has > 80% of collected pure protein and is used for the subsequent experiments. Elution 2 is more dilute and is typically stored as backup or for running protein controls for SDS-PAGE.
39| Preparation of GVs with recombinant GvpC (Steps 39-41: timing = 1 d).
Add recombinant GvpC to ∆GvpC GVs according to the formulation: 2 × OD × 198 nM × volume (in liters) of GVs = nmol of recombinant GvpC. This provides a twofold stoichiometric excess of GvpC relative to binding sites on an average Ana GV, assuming a 1:25 molar ratio of GvpC/GvpA binding based on previous work 26 . The exact volume of recombinant GvpC to be added is calculated based on the molar mass of the particular variant and the concentration of eluted GvpC (measured by Bradford assay according to Steps 34-38). For truncated GvpC variants with a lower GV binding affinity, a higher stoichiometric excess may be added to promote attachment of GvpC to the GV surface. However, note that adding too much excess of GvpC might lead to protein aggregation during dialysis.
40|
Soak the dialysis tubing in PBS for 5 min. Add samples (GVs + recombinant GvpC) into dialysis tubing and clip both sides. Dialyze in 4 liters of PBS with stirring on low speed for at least 12 h.  crItIcal step The length of dialysis tubing used for each sample depends on the total volume of the dialysate, which is determined by the amount of engineered GVs required for the end application. The type of dialysis tubing used (molecular weight cutoff) can change depending on the GvpC variant, as truncated variants may have a much lower molecular weight.
41|
Transfer the dialysate into 2-ml centrifuge tubes and spin at 4-8 °C at 300g for 3 h, or until the subnatant is clear. Remove the subnatant with a syringe with a 21.5-gauge flat needle. Retain the milky white supernatant in the tube. Resuspend GVs in PBS. Repeat this centrifugation step once.
? troublesHootInG  pause poInt Store at 4 °C for up to 3 months. Note that as different GvpC variants have different binding affinities to the GvpA shell, it is advisable to check the hydrostatic collapse profile of the stored GV variant before use in imaging experiments, to ensure that there is no dissociation of recombinant GvpC from the GV surface during storage. 
42| (Optional) Preparation of SpyCatcher-functionalized GVs (Steps 42-45: timing = 5 h). Prepare Ana GVs with GvpC fused to the SpyTag peptide using Steps 39-41.
43| Mix SpyTag-functionalized GVs with SpyCatcher-fused proteins according to the following formulation: 2 × OD × 396 nM × volume (in liters) of SpyTag GVs = nmol SpyCatcher-fused protein. This results in a twofold excess of SpyCatcher to SpyTag in the reaction, based on the stoichiometry described in Step 39. Note that the SpyCatcher-mNeonGreen (SC-mNG) fusion protein used in our published work 14 is expressed separately in E. coli following procedures in Steps 20-23 and using the plasmid containing SC-mNG (details in the Reagents section). SC-mNG is expressed as a soluble and hexahistidine-tagged protein, enabling purification using the same Ni-NTA slurry used for recombinant GvpC purification. Unlike GvpC inclusion bodies, soluble proteins are in the supernatant after cell lysis with Solulyse/DNase (Step 24), allowing direct incubation of the supernatant with the slurry (Step 30). Wash and elution (Steps 31-33) are performed with soluble protein wash buffer and soluble protein elution buffer, respectively, and the protein is desalted into PBS using PD10 desalting columns. Protein quantification is done using the Pierce or Bradford assay before use.
44|
Incubate for 1 h or more at room temperature.
45|
Centrifuge at 300g for 3 h at 4-8 °C or until the subnatant is clear. Remove the clear subnatant with a syringe with a 21.5-gauge needle. Retain the milky white supernatant in the tube. Resuspend the supernatant in PBS. Repeat this centrifugation step one time.
? troublesHootInG  pause poInt Store the GV suspension at 4 °C for up to 3 months.
GV characterization 46|
To characterize the purified GVs, follow the procedure in option A to determine the critical collapse pressure of GVs using pressurized absorbance spectroscopy. Follow option B for DLS measurements and option C for preparing the GV specimens for TEM. 
47| Agarose phantom preparation and sample loading (Steps 47-55: timing = 3 h).
Make a 250-ml solution of 1% (wt/vol) agarose in PBS and microwave for 3 min to ensure dissolution. Ensure that the lid is loosely fastened and swirl the bottle at 1-min intervals to prevent the agarose from settling.
48|
Fasten the lid and put the bottle in a water bath at 50-55 °C for at least 30-45 min to allow the solution to equilibrate to the bath temperature 49| Fill the Nalgene plastic holder (12.5-cm length × 8-cm width, 300 ml) with 150 ml of molten 1% (wt/vol) agarose in PBS. Keep the remaining agarose solution in the water bath for sample loading.
50|
Immerse the multiwell phantom mold on top of the agarose solution.  crItIcal step Remove any small air bubbles with a syringe needle and lower the mold gently onto the surface of the agarose, maintaining a small angle to allow any air trapped on the interface between the agarose and mold to escape.
51|
Let the agarose phantom solidify at room temperature for 1 h.
52|
Carefully remove the multiwell phantom mold without disturbing the agarose beneath.
53|
Prepare the GV samples and controls at 2× the final desired concentration.
54| Prepare a 1:1 mixture of the 1% (wt/vol) agarose in PBS with the GVs or polystyrene beads.  crItIcal step Make sure that the 1% (wt/vol) agarose in PBS is equilibrated to a temperature of 50-55 °C before and during the mixing with GVs or polystyrene beads. Just before mixing with the agarose, place the GV or polystyrene sample for 10-15 s in a 50 °C water bath to warm the sample. This allows proper mixing of agarose with the sample and provides enough time to load the sample into the well before the agarose solidifies.  crItIcal step Do not heat the GV samples to temperatures >50 °C. GV collapse has been observed even for a 10-to 20-s incubation at 65 °C.
55|
Pipette the mixture into the phantom well. The volume of mixture pipetted depends on the dimensions of the well, typically 50-100 µl.
56| Phantom imaging (Steps 56-62: timing = 1 h).
Place the ultrasound acoustic absorber at the bottom of the phantom holder to minimize multiple ultrasound wave reflections during the measurement.
57|
Immerse the phantom in water or 1× PBS.
58|
Perform ultrasound imaging on the Verasonics L11-4v ray-line example script (provided by the manufacturer) using the following parameters: set the transmit frequency to 4.5 MHz, set the number of cycles of the transmitted ultrasound pulse to 3, the F number to 3, the voltage to 2.5 and the persistence to 90. These parameters can be adjusted by the user in the Verasonics MATLAB script defining the ultrasound pulse sequence, and operated via the VSX GUI. Perform the collapse using a high-power pulse at 25 V.
59|
Perform ultrasound imaging at the fundamental frequency with the L22-14v: set the transmit frequency to 11.5 MHz, the number of cycles of the transmitted ultrasound pulse to 6, the F number to 2 and the voltage to 3 V. Those parameters are adjusted in the script and operated via the VSX GUI. 60| Perform ultrasound imaging at the second harmonic frequency with the L11-4v transducer: echoes at the second harmonic frequency are displayed using a 2-MHz-wide band-pass filter centered ~9 MHz. Other parameters are identical to those of the fundamental imaging mode and adjusted in the script. Second harmonic imaging is operated as an option via the VSX GUI. Note that we have recently developed an amplitude modulation strategy that can also be used for highly selective nonlinear imaging of native and engineered GVs 9 .
61| Obtain acoustic multiplexing images by using GVs at OD = 1, a transmit frequency of 6.25 MHz and a voltage of 1.6 V on the L11-4v, with a four-cycle pulse, transmit focus of 20 mm, F number of 2 and persistence of 90. To collapse the GVs, increase the acoustic pressure by lowering the F number to 0.1 and gradually ramping up the voltage. At each collapse step, the transducer is translated in the y and z planes using the Velmex motors to ensure homogeneous collapse over the entire well and field of view.  crItIcal step Ensure that the region of interest in the mouse aligns with the focus of the transducer to acquire optimal images. (ix) Remix the gas vesicles thoroughly by gently pipetting up and down, and then add 100 µl of the GV solution at OD 500,ps ~25 to a 1.5-ml microcentrifuge tube.  crItIcal step Gas vesicles must be mixed thoroughly each time before an injection; they are buoyant and will float up to the top of the tube. Make sure to inject immediately after remixing. (xvi) Imaging under nonlinear contrast mode, acquire ultrasound images before, during and after a bolus injection of GVs, to observe the change in signal from the inflow of gas vesicles. A high-power burst sequence can also be applied to collapse any gas vesicles in the imaging plane and diminish the signal. ? troublesHootInG (xvii) Steps 63B(xiii-xvi) can be repeated for other tissue regions of interest. (xviii) At the end of the imaging session, turn off the isoflurane and remove the mouse from the nose cone. Wait for the animal to completely recover from the anesthesia before returning it back to the cage. production of hyperpolarized Xe and initial nMr calibrations • tIMInG 1 h 64| Preparation of GV samples for MRI: dilute the stock solution of GVs in PBS solution to achieve an OD 500, PS value of ~0.33. For each sample, 2 ml of GVs are needed.  crItIcal step Although Ana and Mega GVs are stable and survive multiple xenon re-deliveries and data sets, Halo GVs are very fragile. Therefore, use a fresh Halo sample for each measurement.
OD measurements should be performed before and after NMR measurements to ensure that GV concentrations stay constant.
65| Startup of the polarizer (Steps 65-72: timing = 20 min).
Turn on the hyperpolarizer according to the manufacturer's protocols.
66|
Select an absolute gas pressure in the system of ~1.2 bar (i.e., 0.2 bar above atmospheric pressure). This pressure is adjusted through the Daq/board-regulated pressure controller behind the sample and will be reached once the hyperpolarizer outlet valve has been opened. The manual pressure regulator directly at the gas tank should be set to a higher value (1.5 to 2 bar).  crItIcal step As the GVs are pressure-sensitive, an excessive pressure set point for the sample could later damage the GVs in solution when performing Step 77. On the other hand, the gas pressure determines the amount of dissolved Xe and eventually the image signal intensity. Considerations regarding the expected spin concentrations are described in box 1.
67| Connect the gas-delivery tubing (coming from the hyperpolarizer) with the gas outlet tubing (going into the pressure controller) using glass connecting tube shown in Figure 5b. 68| Slowly open the outlet valve of the hyperpolarizer to pressurize the gas manifold and to achieve the selected total pressure of 1.2 bar in the entire system. ! cautIon Backflow of air (oxygen) or humidity into the system and the Rb-containing optical pumping cell in the polarizer setup must be avoided at all times to prevent violent reactions with the reactive Rb.
69| Select a total gas flow rate of 250 SMLM through the system for the flow controller between the gas tank and the hyperpolarizer. The pressure controller will now maintain the 1.2 bar while releasing incoming excess gas at the selected flow rate.
Box 1 | General signal considerations • tIMInG 5 min
In comparison with 1 H MRI, the concentration of Xe is ~5 orders of magnitude lower. This is compensated by its higher (~4 orders of magnitude) polarization. Hence, higher Xe partial pressure helps to increase the detectable signal, which is directly proportional to the xenon concentration in solution. The calculation to determine the Xe concentration in solutions can be done as follows using the Ostwald solubility coefficient: procedure 1. For the PBS solution, assume an Oswald solubility coefficient similar to that of water: 0.11 liter/bar or 4.9 mM/bar (1 mole of an ideal gas corresponds to 22.41 liters).
The partial pressure of the Xe fraction (5%) for 1.2 bar of gas mixture in the system is then 0.05 × 1.2 bar, and the concentration of dissolved Xe is [Xe] = 0.11 L/bar × 0.05 × 1.2 bar × 4.9 mM/bar = 295 µM (keep in mind that only 26.4% is the NMR-active isotope 129 Xe). 2. To get an idea of how long it takes to saturate the solution with Xe, consider the following: it has been shown that bubbling water with a 2% (vol/vol) Xe mix at a flow corresponding to 100 SMLM (calibrated to N 2 ; i.e., ~140 SMLM for a 2% (vol/vol) Xe mix) exponentially saturates the solution with Xe with a time constant of ~8 s (see supplementary information of ref. 23) . A 5% (vol/vol) Xe mix at 40 SMLM (described in this protocol) delivers ~29% less Xe per unit of time, and the time constant increases accordingly.
70| Wait until the process temperatures have reached a steady state.
71| Stop the gas flow by setting the flow controller set point to 0 SMLM and isolate the hyperpolarizer by closing its outlet valve.
72| Depressurize the gas manifold by carefully unscrewing the glass tube connector while keeping the polarizer on standby.
73| Checking of the gas-delivery conditions (Steps 73-82: timing = 10 min).
Decide whether the glass phantom should be used with one compartment for a single sample solution or with two compartments for including a second solution (e.g., a reference buffer solution without GVs); in the latter case, insert a 5-mm NMR tube into the glass phantom.
74|
Load the sample solution(s) into the glass phantom and screw the capillary holder onto the inlet thread (distribute the capillaries as needed between the two compartments in case the 5-mm tube has been inserted). Make sure that the filling level is not too high, so that the NMR coil can also detect some of the gas atmosphere on top of the solution.
75| Connect the gas-delivery tube from the hyperpolarizer setup to the capillary holder of the phantom and the gas outlet tube to the other chem thread of the glass phantom.
76| Select a total flow rate through the polarizer of 250 SMLM and activate the flow. This will ensure that gas is flowing into the system once the next step is performed.
77|
Carefully pressurize the PFA tubing system by slowly opening the outlet valve of the hyperpolarizer to reach the overpressure of 0.2 bar.  crItIcal step Make sure that the shortcut valve is always open for pressurizing or depressurizing the sample; this avoids abrupt pressurization that could push the sample solution out of the glass phantom into the PFA tubing, which can later contaminate the flow or pressure controller.  crItIcal step When pressuring the GV-containing sample with a xenon gas mix, a fast change in pressure must be avoided and a rate of 0.1 bar/30 s should not be exceeded to ensure that the GVs remain intact.
78|
Once the pressure has stabilized, ensure that the total flow rate of 250 SMLM through the polarizer is still active while the shortcut valve is open; this flow will now go through the bypass without bubbling the sample.
79|
To bubble the sample, adjust the sample delivery flow to 40 SMLM.
80|
For activating the flow, the pulse sequence must be executed. However, all radio frequency (RF) pulses should be turned off, as there is no sample in the NMR coil that absorbs the transmitted power. To do so, select the pulse-acquire FID sequence including the TTL triggers and set the amplitude of the excitation pulse to 0.
81| Choose a bubble time of ~10-20 s and a waiting time after bubbling of ~1-2 s.
82| Set the number of repetitions to 5-10 and start the sequence while watching the sample for sufficient gas dispersion during periodic gas delivery and possible unwanted excessive foam formation inside the glass phantom. Ensure that any foam and gas bubbles disappear within the waiting time after bubbling (typically 1-2 s).  crItIcal step Prolonged bubbling could collapse GVs via shear forces. The flow of gas through the sample should be long enough to have an adequate xenon signal but short enough to avoid stressing the GVs too much. The subsequent waiting time should be as short as possible to minimize the longitudinal relaxation of the xenon but long enough to ensure that all bubbles collapse. ? troublesHootInG 83| Preparative MRI measurements (Steps 83-91: timing = 10 min). Insert the pressurized phantom carefully into the NMR probe that is already mounted inside the magnet in its correct position.
84|
If desired, adjust the temperature of the sample with the VTU of the spectrometer. The sample data from Figure 6 were acquired at room temperature (T = 298 K).  crItIcal step If another set point, e.g., body temperature, is chosen, the sample might need 20-40 min to reach stable temperature. It is possible to continue with the next steps, but Step 87 should not be performed until stable conditions are reached.
85| Tune and match the 1 H and 129 Xe resonators, perform a global automatic shim on the sample and acquire a proton reference image with automated adjustments for 1 H resonance frequency, reference attenuation (flip angle) and receiver gain according to the spectrometer manufacturer's protocol.
86|
Set the Xe delivery flow to 40 SMLM, 10-s bubbling time and 2-s wait time or as optimized in Step 82.
87| Take a 1D Xe NMR spectrum with the pulse-acquire FID sequence including the TTL triggers with an ~350 p.p.m. bandwidth and four signal averages. If the amplitude for a flip angle of ~90° is not known, proceed with the steps in box 2 (and Fig. 6f-i) to determine the reference pulse.
88|
Perform Fourier transform and automatic phase correction to display the NMR spectrum. Find the resonance frequency of the left intense peak (Fig. 6a) and use it as the transmitter frequency for further 129 Xe MRI acquisition. ? troublesHootInG 89| For the imaging experiments to follow, enter the reference pulse power into the pulse sequence control interface (typically the pulse amplitude for a 1-ms block pulse to achieve a 90° flip of the magnetization). Switch to an MRI sequence and choose the same bubbling time, wait time and transmitter frequency.
90|
Ensure that the excitation for either the EPI or the RARE sequence is effectively a 90° pulse and that other sequence parameters are set as in the equipment preparation section. The number of acquisitions should be set to one.
Box 2 | Flip-angle calibration for hyperpolarized xenon • tIMInG 10 min
Flip-angle calibration is usually done with a series of repetitive excitations and subsequent analysis of the obtained signal intensities. It is used to derive pulse amplitudes for the shaped excitation pulses, as well as to determine the saturation power in µT. As hyperpolarization does not self-replenish, it is convenient to use a constant small flip-angle excitation and analyze the signal decay after a single Xe delivery as follows: additional materials • Nonselective NMR pulse sequence for acquiring a series of Xe solution signals after a single Xe delivery. This is implemented by using a simple (pulse-acquire-crusher) sequence with fast repetition between the excitations. As an example, the sequence can have a 100-µs block excitation pulse of adjustable amplitude, followed by a 9.72-ms FID sampling time (99 data points collected) and crusher gradients to remove all remaining transverse magnetization.
• Evaluation tool such as a gnuplot (https://sourceforge.net/projects/gnuplot/) fitting routine or Origin (https://www.origin.com/ usa/en-us/store/download) to fit the data to a user-defined exponential decay model function. procedure 1. Choose the above-mentioned nonselective NMR sequence with single Xe delivery and multiple acquisitions. 2. Select a relatively small excitation pulse amplitude (assuming α = ~7°-11°).  crItIcal step If the amplitude is too high, the signal decay will be either too fast or not monotonous; if the amplitude is too low, the observed signal will be too noisy over the entire series. (Fig. 6f,g ). For an evaluation without custom-made scripts such as a gnuplot fitting routine, perform the following steps. 5. Export the magnitude spectra data as a .txt file and load them into Origin. 6. Perform ParaVision standard postprocessing: each spectrum contains 128 data points, of which only the peak heights are important. 7. Plot the concatenated spectra and evaluate the envelope formed by the peak heights. This envelope can be reconstructed with the '↓Analysis ↓Signal Processing ↓Envelope' tool in Origin using ~100 smoothing points. 8. Fit the envelope using the function I(x) = M 0 + I 0 sin α (cos α) (x/p -1) with α as the desired unknown flip angle, M 0 as a constant offset representing the nonvanishing noise level for large x, and p as the fixed number of displayed data points between two peaks. The fit should be performed for the range where the actual data is still above the noise level (Fig. 6h,i) . This evaluation neglects T 1 relaxation during the short acquisition time. Fitting the observed signal intensity to this function therefore yields the flip angle α that the 100-µs block pulse achieved for the selected pulse amplitude. 9. The scaling factor for the pulse amplitude of a 10-fold-longer standard block pulse (1 ms) is then given by 90°/(10 × α). Use this for the reference gain for all derived pulse amplitudes. 10. Knowing the amplitude for a 90° pulse of 1-ms length, derive the pulse power in µT as follows: a full nutation takes 4 ms, and hence the precession about the B 1 field occurs at 250 Hz. The gyromagnetic ratio for 129 Xe is γ = 11.777 kHz/mT. Hence, the applied field strength is B 1 = 250/11,777 mT = 0.0212 mT = 21.23 µT. This can be used to derive the pulse powers for a desired saturation level in µT. 91| Run the Xe MRI acquisition without any saturation pulses (deactivate the magnetization transfer (MT) module) and without a phase-encoding gradient (GSP in Bruker's ParaVision), and set the receiver gain such that the maximum incoming signal reaches ~30% of the full analog-to-digital converter (ADC) range. Hyper-cest MrI 92| For Hyper-CEST MRI acquisition, follow the steps in option A for acquiring an entire image series with different saturation offsets for obtaining spectral information of the CEST response (e.g., Fig. 6b) or option B for acquiring data with only one on-resonant and one off-resonant saturation to obtain a single Hyper-CEST image (e.g., Fig. 6c-e) . Spectral information is obtained when changing the frequency of the saturation pulse. This results in a so-called z-spectrum whose characteristic shape is influenced by xenon's exchange properties with the GV. Option A should be performed if the exact resonance frequency of Xe inside the GVs is not known. Images with improved quality can then be obtained subsequently with option B. ! cautIon Ensure that the power limits for the NMR coil are not exceeded, as this might permanently damage the coil.  crItIcal step It is not useful to choose a saturation time that exceeds the T 1 relaxation time of Xe in water; the signal loss is then dominated by intrinsic relaxation and not by the CEST effect 24 .  crItIcal step The choice of the right saturation conditions is critical to optimal z-spectra quality and for correct interpretation of saturation transfer in xenon MR images. As a rule of thumb, short but strong saturation is desired first. If multiple agents (different GV types in this context) are present, then the saturation strength should be reduced and the saturation time should be adapted similarly. (iii) Start the image series acquisition and make sure that the system does not perform any auto-adjustments that overwrite any of the previous settings (GOP command in Bruker's ParaVision).  crItIcal step If the images are acquired individually because the operating system does not allow an array of measurements as in Bruker's ParaVision, it is important that all images be taken with the same receiver gain and that the system does not automatically readjust the receiver gain before each acquisition. (iv) Open the image evaluation tool of the spectrometer software and draw a region of interest (ROI) for signal integration in the xenon MR images that were acquired for different saturation pulse frequencies. 
Poor GV yield Cultures are not confluent
Incomplete lysis
Collapse of GVs Inefficient retrieval of buoyant cells from the separatory funnel Allow cultures to grow for a few more days. Confluency is determined by the color and turbidity of the cultures as described in the procedure and shown in Figure 2 Dilute the concentrated cell suspension with lysis buffer and/or allow lysis to proceed longer Make sure that the cultures are not subjected to agitation >100 r.p.m., and handle flasks gently while transporting and placing them on hard surfaces Thoroughly wash the inner walls of the funnel with media/ buffer to retrieve the buoyant cells sticking to the sides (especially for Halo) Step 92A, imaging series and z-spectrum: one experimental session: 45 min
Step 92B, single Hyper-CEST image from two saturation frequencies: one experimental session: 20 min Steps 93-98, shutting down of the system: 10 min box 1, general signal considerations: 5 min box 2, flip-angle calibration for hyperpolarized xenon: 10 min antIcIpateD results GV expression and purification ana and Halo GV expression and purification. Healthy, viable Ana and Halo cultures look dark green (Fig. 2c) and light pink (Fig. 2d) , respectively, upon reaching confluency. Figure 2e ,f shows the separation of buoyant Ana and Halo cells from spent medium. For Halo cultures, the buoyant cells are visible as a thin layer or ring of milky pink at the top of the liquid phase. After lysis, the lysate will appear milky because of the presence of GVs. After one round of centrifugally assisted floatation, the GVs will appear as a white layer at the top with a green (Ana) or pink (Halo) liquid subnatant, along with a pellet of cell debris at the bottom. For the Halo, a mixed layer of white (Halo GVs) and milky pink (unlysed Halo cells) may be visible after the initial spins. Figure 2g ,h shows representative images of the purified Ana and Halo GVs in 2-ml tubes after the final spin, with the white GVs forming a dense layer at the top and a clear subnatant of PBS. Figure 2j shows tubes containing milky white solutions of purified Ana and Halo GVs (~OD 500,ps = 6) resuspended in PBS. The typical GV yield is ~3 ml of OD 500,ps = 10 for Ana and Halo GVs per flask of culture.
Mega GV expression and purification in E. coli. Although native expression of Ana and Halo GVs usually results in the majority of the cells being buoyant, most of the E. coli cells heterologously expressing Mega GVs reside in the pellet after centrifugation. In our experience, the typical yield of Mega GVs is ~1.5 mg/l cells per unit of OD 600 . Figure 2i shows a representative image of purified and unclustered Mega GVs forming dense white layer at the top, with a clear subnatant of PBS. Figure 2j shows a milky white solution of purified and unclustered Mega GVs resuspended in PBS (~ OD 500,ps = 6). 
GV functionalization
Ana GvpC is purified from inclusion bodies in E. coli. The recombinant GvpC can be harvested with yields of up to 40 mg protein per liter of culture. The inclusion bodies yield >95% pure protein (Fig. 7a) . GvpC-based functionalization relies upon complete removal of the native Ana GvpC layer before reconstitution with recombinant protein. Urea treatment results in nearly complete (>95%) removal of native GvpC, indicated by the absence of GvpC on SDS-PAGE (Fig. 7a) and a lowered critical collapse pressure (shown in the following section on GV characterization). GVs retain their milky white appearance throughout the functionalization process. The binding of recombinant GvpC variants to GVs can be assayed by SDS-PAGE and Coomassie staining. ∆GvpC Ana GVs do not exhibit a band ~25 kDa (molecular weight of GvpC), whereas wild-type and truncated GvpC variants bind to GVs and exhibit a distinct band corresponding to their theoretical molecular weight (Fig. 7a) . Figure 7b shows an application using dual-functionalized GVs for targeted cell-specific imaging. In this example, Ana GVs functionalized with GvpC fused to peptide RGD are chemically conjugated to Alexa Fluor 488. The functionalized GVs bind to integrin receptors on glioblastoma cells via the RGD motif and the fluorescent labeling of GVs enables rapid assessment of targeting efficacy using confocal microscopy. SpyTag-GvpC binds to GVs with similar productivity and stoichiometry as wild-type GvpC. We have previously shown that each modified GV has an average of 1,000 SpyTag functionalities 14 . The collapse pressure of SpyTag GVs is not altered upon SpyCatcher binding, indicating that attachment of a large 37.9-kDa protein to the GV surface does not adversely affect GvpC strengthening of the GV wall 14 .
Functionalization of SpyTag-GVs with SpyCatcher-GFP enables multimodal imaging of GVs with ultrasound and fluorescence. Ultrasound images were acquired in an agarose phantom with a Verasonics L22-14V transducer at 19 MHz, 5.0 V and F number 3. The ultrasound images show similar echogenicity between fluorescently labeled GVs and wild-type and unreacted controls (Fig. 7c) . Optical images taken through the green channel of a BioRad Chemidoc MP system indicate that SpyTag-SpyCatcher-GFP labeled GVs are fluorescent (Fig. 7c) . Fluorescence quantification of Halo GVs after chemical conjugation to Alexa Fluor 488 indicates that functionalized GVs are ~40-fold more fluorescent than native GVs. 6 . It is also important to note that not all Halo GVs have a spindle morphology, and a small subpopulation may appear more cylindrical with biconical ends 27 . Ana GVs that are produced in their native host are usually longer and wider than heterologously expressed Mega GVs. Typical GV dimensions obtained from TEM images are summarized in table 4.
The high resolution provided by TEM allows the visualization of ribs on the surface of the gas vesicles at higher magnifications. Figure 7g shows intact and collapsed Ana GVs, demonstrating that collapse causes complete rupture and opening of the protein shell, leading to a flattened pancake-like structure. GVs chemically functionalized with biotin can be coated with streptavidin and visualized by TEM 8 .
In vitro ultrasound imaging
Typical ultrasound images acquired in the fundamental mode and after second harmonic filtering show contrast from intact wild-type (WT) and ∆GvpC Ana GVs (Fig. 8a, top panel) . Acoustic collapse of GVs leads to elimination of ultrasound signal (Fig. 8a, bottom panel) , confirming that contrast arises from the intact GVs. Lowering of collapse pressure is typically associated with higher nonlinear signals from GV samples, allowing tuning of GV harmonic response by modification or removal of GvpC. The ultrasound contrast from Halo GVs and their utility for nonlinear imaging in vitro and in vivo has been demonstrated in our previous work 8 . The acoustic behavior of Halo GVs at ultrasound frequencies of 12.5-27.5 MHz has also been investigated through modeling and experiments, suggesting acoustic buckling as the mechanism underlying generation of nonlinear signals 10 . In parallel, we recently developed an amplitude modulation scheme taking advantage of the nonlinear pressure dependence of backscattered signals in engineered Ana GVs, allowing selective imaging of these nanostructures 9 . 
In vivo ultrasound imaging
When imaging gas vesicles in vivo, we suggest starting with a vascularized organ such as the liver. A normal liver will look homogeneous under B-mode ultrasound, with vessel cross-sections appearing as hypoechogenic regions (Fig. 8b, left panel) . When imaging a mouse in the transverse plane, it is possible to locate a region of the liver containing the IVC.
After gas vesicles are administered intravenously via the lateral tail vein, nonlinear contrast enhancement will be observed first in the IVC, followed by the liver (Fig. 8b) . Using the VevoLAB software, regions of interest (ROIs) encompassing the IVC and liver can be drawn, and a time intensity curve of the mean contrast signal change over time within each ROI can be plotted.
As shown in Figure 8c , once a 50-µl bolus of gas vesicles has been injected, an initial bulk signal is observed in the IVC, which will decrease over time as the gas vesicles are dispersed into the circulation. Signal enhancement in the liver will follow a few seconds after with a steady signal increase and then a plateau. The signal plateau in the liver is probably due to the uptake of nonfunctionalized gas vesicles by the Kupffer cells, similar to that for many other nano-sized particles. This contrast signal can then be eliminated by using a high power burst that will collapse all the gas vesicles in the imaging plane.
It is possible to engineer Ana GVs to produce enhanced nonlinear signals in vivo (Fig. 8d,e) . After bolus injection of GVs, ultrasound imaging of the IVC is performed in fundamental and harmonic modes for up to 1 min (transmission at 4.46 MHz and reception filtered ~4.46-and 8.9-MHz center frequencies, respectively). The mean signal intensity plotted as a function of time (Fig. 8d,e) shows that ∆GvpC Ana GVs produce higher harmonic signals as compared with Ana GvpC WT in vivo, whereas their fundamental signals are comparable. This observation is also consistent with the in vitro data in Figure 8a .
Hyperpolarized Xe MrI imaging of GVs
Typical GV concentrations in the nanomolar to picomolar range will not allow direct observation of the GV-bound Xe. A 129 Xe NMR spectrum therefore shows only the signal from dissolved xenon gas (assigned to 0 p.p.m.) and the resonance from Xe gas on top of the solution (appearing ~190 p.p.m. to the right of the solution peak) (Fig. 6a) . Data obtained in Step 92A(v) should look similar to the spectrum in Figure 6b , except that it is not yet normalized. Taking the relaxation and saturation-free reference signal from Step 92A(viii) into account, the spectrum should yield intensities between 0 and 1, similar to Figure 6b . It should be noted that the longer the saturation time, the more the baseline has dropped below 1. 
